Skip to main content

$0.700 0.005 (0.72%)

High

$0.72

Low

$0.70

Trades

33

Turnover

$39,512

Volume

56,305
30 June 2023 at 4:10pm
Register to track CU6 and receive email alerts.

Recruitment opens for Phase II trial in Prostate Cancer

StockBot

416,823 posts

CU6 released this announcement to the ASX on 5 September 2022, 8:56. The announcement is marked as price sensitive, and is 3 page(s) in length and 334.84kb in size.

You can view all announcements from CU6 and see how they appear on a price chart on the announcements page.

At the date of this announcement, CU6 was 0.012% short sold according to ASIC data. It was ranked the 613th most shorted stock on the ASX. It is now ranked as the 37th most shorted stock on the ASX with 7.699% of total shares short sold as of the latest reported data (26 May 2026).

Other Recent Announcements from CU6
Cleansing Notice 28 June 2023, 13:19
Application for quotation of securities - CU6 28 June 2023, 13:13
Clarity Establishes US Center of Excellence for Research 28 June 2023, 9:08
Recruitment opens for Phase II trial in Prostate Cancer 5 September 2022, 8:56
Preliminary Final Report 24 August 2022, 13:05
Paediatric neuroblastoma trial advances to cohort 3 23 August 2022, 9:53
Imaging trial in prostate cancer opens for recruitment 22 August 2022, 10:01
You must login or register to post a comment.

You must be logged in to post a reply.

Register to track CU6 and receive email alerts.